Tags

Type your tag names separated by a space and hit enter

[Short-acting insulin analogs].
Ned Tijdschr Geneeskd. 1998 Feb 21; 142(8):397-400.NT

Abstract

Patients with diabetes mellitus type I usually are treated with a multiple injection regimen comprising rapid-acting insulin before meals and intermediate-acting insulin at bedtime. Recently, the rapid-acting insulin analogue insulin LISPRO was introduced on the Dutch market. This form of insulin is very rapidly taken up into the bloodstream from the subcutaneous tissue. The advantages of the use of insulin LISPRO are the comfort of injecting the insulin just before a meal, the more rapid correction of incidental hyperglycaemia and the slightly lower incidence of (nocturnal) hypoglycaemia in comparison with conventional rapid-acting insulin. There is no argument in favour of switching diabetics to insulin LISPRO if they are well-controlled with normal rapid-acting insulin and have few episodes of hypoglycaemia. In some persons the duration of action of insulin LISPRO may be too short, leading to preprandial hyperglycaemia. This can be avoided by using a second injection of intermediate-acting insulin, either before breakfast or before lunch.

Authors+Show Affiliations

Wolffenbuttel BH
Academisch Ziekenhuis, afd. Endocrinologie en Stofwisselingsziekten, Maastricht.
Heine RJ
No affiliation info available

MeSH

Diabetes Mellitus, Type 1HumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulinInsulin LisproInsulin, Isophane

Pub Type(s)

English Abstract
Journal Article

Language

dut

PubMed ID

9562773

Citation

Wolffenbuttel, B H., and R J. Heine. "[Short-acting Insulin Analogs]." Nederlands Tijdschrift Voor Geneeskunde, vol. 142, no. 8, 1998, pp. 397-400.
Wolffenbuttel BH, Heine RJ. [Short-acting insulin analogs]. Ned Tijdschr Geneeskd. 1998;142(8):397-400.
Wolffenbuttel, B. H., & Heine, R. J. (1998). [Short-acting insulin analogs]. Nederlands Tijdschrift Voor Geneeskunde, 142(8), 397-400.
Wolffenbuttel BH, Heine RJ. [Short-acting Insulin Analogs]. Ned Tijdschr Geneeskd. 1998 Feb 21;142(8):397-400. PubMed PMID: 9562773.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Short-acting insulin analogs]. AU - Wolffenbuttel,B H, AU - Heine,R J, PY - 1998/5/1/pubmed PY - 1998/5/1/medline PY - 1998/5/1/entrez SP - 397 EP - 400 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 142 IS - 8 N2 - Patients with diabetes mellitus type I usually are treated with a multiple injection regimen comprising rapid-acting insulin before meals and intermediate-acting insulin at bedtime. Recently, the rapid-acting insulin analogue insulin LISPRO was introduced on the Dutch market. This form of insulin is very rapidly taken up into the bloodstream from the subcutaneous tissue. The advantages of the use of insulin LISPRO are the comfort of injecting the insulin just before a meal, the more rapid correction of incidental hyperglycaemia and the slightly lower incidence of (nocturnal) hypoglycaemia in comparison with conventional rapid-acting insulin. There is no argument in favour of switching diabetics to insulin LISPRO if they are well-controlled with normal rapid-acting insulin and have few episodes of hypoglycaemia. In some persons the duration of action of insulin LISPRO may be too short, leading to preprandial hyperglycaemia. This can be avoided by using a second injection of intermediate-acting insulin, either before breakfast or before lunch. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/9562773/[Short_acting_insulin_analogs]_ L2 - https://medlineplus.gov/diabetesmedicines.html DB - PRIME DP - Unbound Medicine ER -